Health ❯ Healthcare

Obesity Treatment

Weight Loss Drugs Weight Management Weight Loss Medications GLP-1 Drugs Medications GLP-1 Medications GLP-1 Agonists GLP-1 Receptor Agonists Semaglutide Drug Sales Patient Access Pharmaceutical Research Injectable Medications Fat Injections Diabetes Management CagriSema Biotechnology Weight Loss Drug Affordability Pharmaceutical Products Oral Medications Prescription Drugs Market Competition Diabetes Medications Self-Pay Programs Eli Lilly Clinical Research Pharmaceuticals Long-term Care Drug Efficacy

States Curb Medicaid Coverage as First GLP‑1 Weight‑Loss Pill Debuts and Cash Prices Fall

Coverage cutbacks shift more of the cost burden onto patients who can least afford it.

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

Lilly Cuts Zepbound Cash Prices on LillyDirect as GLP‑1 Price Competition Deepens

Berenberg Upgrades Novo Nordisk to Buy, Sets DKK425 Price Target

FDA Ends GLP-1 Drug Shortages, Triggering New Pricing and Coverage Moves